0GTN.LSE BioGaia AB ser. B
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 1.52%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is 0GTN.LSE undervalued?
Graham numberThe Graham number of BioGaia AB ser. B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioGaia AB ser. B fundamental analysis
No fundamental analysis for BioGaia AB ser. B yet.
BioGaia AB ser. B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioGaia AB ser. B
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. I…
Full company profileBioGaia AB ser. B financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioGaia AB ser. B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 535M | 615M | 742M | 768M | 747M | - | - | - |
| Gross Profit | 388M | 463M | 556M | 564M | 547M | - | - | - |
| Operating Income | 199M | 234M | 277M | 243M | 228M | - | - | - |
| Net Income | 228M | 181M | 215M | 187M | 180M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 489M | 576M | 660M | 666M | 1.91B | - | - | - |
| Total Liabilities | 73.8M | 112M | 155M | 158M | 167M | - | - | - |
| Shareholders' Equity | 415M | 464M | 505M | 508M | 1.75B | - | - | - |
| Cash & Short-term Investments | 243M | 311M | 290M | 219M | 1.47B | - | - | - |
| Total Debt | - | - | - | 17.3M | 20.7M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 148M | 223M | 183M | 148M | 221M | 222M | 319M | - |
| Capital Expenditure | 5.61M | 26.6M | 13.5M | 32.3M | 16.1M | 6.38M | 17.9M | 0.00 |
| Ratios | ||||||||
| ROE | 54.8% | 38.9% | 42.6% | 36.9% | 10.3% | - | - | - |
| ROA | 46.5% | 31.3% | 32.6% | 28.1% | 9.4% | - | - | - |
| Net Profit Margin | 42.6% | 29.4% | 29.0% | 24.4% | 24.1% | - | - | - |
| Debt to Equity | - | - | - | 0.03x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioGaia AB ser. B dividends
BioGaia AB ser. B has not paid dividends in the last 9 fiscal years.
Last stock split: 5:1 on May 18, 2022.
Who owns BioGaia AB ser. B
- Insiders 17.00%
- Institutions 52.36%
- Public & others 30.64%
- Free float 83.9M
BioGaia AB ser. B company profile
- Company name
- BioGaia AB ser. B
- Ticker
- 0GTN.LSE
- ISIN
- SE0017769995
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 251
- Fiscal year end
- December
- Address
- Kungsbroplan 3, Stockholm, Sweden, 112 27
- Phone
- 46 8 55 52 93 00
- Website
- biogaiagroup.com
About BioGaia AB ser. B
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
BioGaia AB ser. B management
10- Ms. Theresa P. AgnewCEO & President · born 1966
- Mr. Alexander Kotsinas M.Sc. (Eng.).Executive VP & CFO · born 1967
- Ludvig MilessonChief Operating Officer · born 1977
- Mr. Gianfranco GromponeChief Scentific Officer · born 1975
- Ms. Caroline MoforsExecutive VP & Chief Legal Officer · born 1972
- Ms. Linda HagglundChief Marketing Officer · born 1973
- Ms. Angelika KjelldorffChief Human Resources Officer · born 1969
- Minna TähtinenManaging Director Finland
- Jennifer CherryManaging Director USA
- Mr. Darryl MalletteManaging Director Canada